

Characterization of Psychotropic PRN Medications in a Psychiatric ICU



Marina Casol, B.Sc. (Pharm); Angela Tong, B.Sc. (Pharm), ACPR.; Joan C.Y. Ng, B.Sc. (Pharm), ACPR, PharmD.; Muhammad Mansoor Anwar, MBBS, MRCPsych, FRCPC; Rumi McGloin, B.Sc. (Pharm), ACPR, PharmD.

Background

- Pro re nata (PRN) antipsychotics and benzodiazepines routinely used to rapidly stabilize acutely agitated patients¹
- Limited evidence to guide pharmacological treatment²
- Non-pharmacological de-escalation strategies should be considered before administering medications³
- Incomplete documentation of efficacy and safety of PRN administration¹
- PRN antipsychotics increase risk of adverse effects secondary to polypharmacy and high daily dose exposure⁴
- PRN benzodiazepines have potential for tolerance, sedation and dependence³

Objectives

- Primary:**
 - Describe the prescribed medication, dosing range, route, frequency, indication, and documentation practices for PRN psychotropic medications
- Secondary:**
 - Describe non-pharmacological interventions used for acute stabilization
 - Describe whether total daily PRN dose of antipsychotic drugs is within Health Canada (HC) limits
 - Describe adverse effects and events

Methods

- Design:** Retrospective cohort chart review
- Inclusion criteria:**
 - Age ≥ 18 years
 - Admitted to psychiatric intensive care unit (ICU) at Surrey Memorial Hospital (SMH) between June and September 2018
 - Received PRN antipsychotics and benzodiazepines
- Exclusion criteria:**
 - Admitted to SMH Emergency Department (ED) at any point during psychiatric ICU admission
- Sample size:**
 - Convenience sample, selected in reverse chronological order
- Definitions:**
 - Documentation: within 4 hours of dose given in nursing notes
 - Adverse effect: Naranjo scale (documented if ≥ 4 "possible")
 - Adverse event: unintended patient harm or staff harm occurring within 4 hours prior to administration of PRN medication

Results

Table 1: Patient Characteristics

	N=32
Male, n (%)	22 (69)
Age (years), median (IQR)	34 (27-50)
Psychiatric ICU length of stay (days), median (IQR)	14 (9-20)
Admitting Diagnosis, n (%)	
<i>Schizoaffective related disorder</i>	11 (34)
<i>Schizophrenia</i>	8 (25)
<i>Bipolar 1 disorder</i>	4 (13)
<i>Drug induced psychosis</i>	3 (9)
<i>Other</i>	6 (19)
Illicit substance use, n (%)	19 (59)
Adverse events*, n (%)	6 (19)
<i>Total number of events</i>	14

*Mostly related to staff harm; none resulted in serious injury

Table 2: Characteristics of Psychotropic PRN Orders

	N=123
Total number of psychotropic PRN orders	N=123
Number of PRN orders per patient, median (IQR)	3 (2-3)
24 hour maximum prescribed, n (%)	121 (98)
Frequency prescribed, n (%)	119 (97)
Prescriber indication, n (%)	41 (33)
<i>Agitation and/or anxiety</i>	25 (20)
<i>Agitation/anxiety or insomnia</i>	7 (6)
<i>If refuse regular medication</i>	5 (4)
<i>Other</i>	4 (3)
Antipsychotic PRN orders exceeding total daily HC dose limits, n (%)	10 (8)

Table 3: Characteristics of Psychotropic PRN Administrations

	N=1179
Total number of psychotropic PRN administrations	N=1179
Number of PRNs administered per patient, median (IQR)	27 (12-53)
PRNs documented for effectiveness, n (%)	795 (67)
PRNs documented for nursing rationale, n (%)	1164 (99)
Non-pharmacological method documented prior to PRN administration, n (%)	559 (47)
<i>Two or more techniques</i>	161 (14)
<i>Redirection</i>	119 (10)
<i>Clear mutual expectations</i>	92 (8)
<i>Education/teaching</i>	61 (5)
<i>Reassurance</i>	41 (3)
<i>Listening techniques</i>	37 (3)
<i>Other</i>	48 (4)




Figure 1: Proportion of Psychotropic PRN Administrations

Limitations

- Single centre, retrospective design
- Total daily dose that included regular antipsychotic administrations in addition to PRN antipsychotics was not assessed
- De-escalation strategies that did not result in PRN administration were not assessed
- Exclusion of patients who were admitted to ED may have led to missed adverse effects

Conclusions

- PRN psychotropic medications administered throughout the psychiatric ICU admission
- There is potential to cause harm due to exceeding 24 hour Health Canada dose maximums for antipsychotics
- Non-pharmacological de-escalation methods and documentation of effectiveness following PRN administration could be optimized
- Further education needed regarding the benefits of prescribing specific indications with each PRN order
- Further studies are needed in assessing appropriateness of psychotropic PRN medications

References

- Baker JA, Lovell K, Harris N. A best-evidence synthesis review of the administration of psychotropic pro re nata (PRN) medication in in-patient mental health settings. *J Clin Nurs.* 2008;17:1122-31.
- Douglas-Hall P, Whicher EV. As required medication regimens for seriously mentally ill people in hospital. *Cochrane Database Syst Rev.* 2015;(12):1-28.
- Stewart D, Robson D, Chaplin R, Quirk A, Bowers L. Behavioral antecedents to pro re nata psychotropic medication administration on acute psychiatric wards. *Int J Ment Health Nurs.* 2012;21:540-9.
- Martin K, Arora V, Fischler I, Tremblay R. Descriptive analysis of pro re nata medication use at a Canadian psychiatric hospital. *Int J Ment Health Nurs.* 2017;26:402-8.